Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

Company To Initially Target 70 Cancer Centers

 
• By Alaric DeArment
  
Form close up, fountain pen and approved stamped on a document. Soft focus.
Blueprint Medicines received FDA approval for Ayvakit in advanced systemic mastocytosis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip